The combination of bortezomib and dexamethasone can increase plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), a biomarker for cardiomyopathy, and risk of death especially among patients with advanced disease (36, 37). This evidence concerns the gene NPPB and cardiomyopathy.